The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 48 (2) , 396-401
- https://doi.org/10.1016/j.jacc.2006.05.009
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The effect of statin therapy on lipoprotein associated phospholipase A2 levelsAtherosclerosis, 2005
- Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined HyperlipidemiaJournal of the American College of Cardiology, 2005
- Effects of Atorvastatin Versus Other Statins on Fasting and Postprandial C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Patients With Coronary Heart Disease Versus Control SubjectsThe American Journal of Cardiology, 2005
- Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk ScoresCirculation, 2004
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- Diabetes and AtherosclerosisJAMA, 2002
- Effect of Statin Therapy on C-Reactive Protein LevelsJAMA, 2001
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery diseaseAtherosclerosis, 2000
- Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study)Thrombosis and Haemostasis, 2000
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997